These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 33862)

  • 21. Comparative tolerability of labetalol versus propranolol, atenolol, pindolol, metoprolol, and nadolol.
    Burris JF; Goldstein J; Zager PG; Sutton JM; Sirgo MA; Plachetka JR
    J Clin Hypertens; 1986 Sep; 2(3):285-93. PubMed ID: 2878065
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Twenty-four-hour blood pressure profile and blood pressure variability in untreated hypertension and during antihypertensive treatment by once-a-day nadolol.
    Mancia G; Ferrari A; Pomidossi G; Parati G; Bertinieri G; Grassi G; Gregorini L; di Rienzo M; Zanchetti A
    Am Heart J; 1984 Oct; 108(4 Pt 2):1078-83. PubMed ID: 6148866
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nadolol: a new beta-adrenoceptor antagonist.
    Frishman WH
    N Engl J Med; 1981 Sep; 305(12):678-82. PubMed ID: 6115316
    [No Abstract]   [Full Text] [Related]  

  • 24. [The effect of the beta-blocker nadolol on the second messenger, serum cyclic adenosine monophosphate, and on blood pressure and heart rate].
    Weth G; Schneider J; Rodatz H; Haubitz I
    Arzneimittelforschung; 1985; 35(11):1711-3. PubMed ID: 2868733
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Our experience on the clinical use of nadolol].
    Trinchero R; Moratti M; Ghisio A; Pomari F; Artesani S; Barbano G
    Minerva Cardioangiol; 1985 Oct; 33(10):629-34. PubMed ID: 2867492
    [No Abstract]   [Full Text] [Related]  

  • 26. Mediation of blood pressure by nadolol and alpha methyldopa.
    Jenkins AC; Rosenthal J; Stumpe KO
    Practitioner; 1981 Mar; 225(1353):405-9. PubMed ID: 6115378
    [No Abstract]   [Full Text] [Related]  

  • 27. Effect of a long acting beta-adrenoceptor blocker on diurnal variation of cardiac dysrhythmias.
    Mir MA
    Postgrad Med J; 1986 Mar; 62(725):175-8. PubMed ID: 2872664
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nadolol and placebo comparison study in the prophylactic treatment of migraine.
    Freitag FG; Diamond S
    J Am Osteopath Assoc; 1984 Dec; 84(4):343-7. PubMed ID: 6150909
    [No Abstract]   [Full Text] [Related]  

  • 29. [A new beta 1-receptor blocker in the therapy of essential hypertension and angina pectoris].
    Burkart F; Stamm G; Witassek F
    Schweiz Med Wochenschr; 1989 May; 119(18):575-81. PubMed ID: 2568685
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Field study: long-term antihypertensive therapy with the beta blocker nadolol in a once-a-day dosage - an outpatient study of Swiss medical practices].
    Bertel O; Conen D; Renggli I
    Schweiz Rundsch Med Prax; 1983 Feb; 72(8):264-8. PubMed ID: 6132374
    [No Abstract]   [Full Text] [Related]  

  • 31. Comparison of the antihypertensive and renal effects of tertatolol and nadolol in hypertensive patients with mild renal impairment.
    Fallo F; Gregianin M; Bui F; Macrì C; Folino P; Mantero F
    Eur J Clin Pharmacol; 1991; 40(3):309-11. PubMed ID: 1676368
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Efficacy of the nadolol-bendroflumethiazide combination in the treatment of arterial hypertension].
    Zecchi P; Bellocci F; Santarelli P; Iannarelli M
    Clin Ter; 1986 Jan; 116(1):19-24. PubMed ID: 2870837
    [No Abstract]   [Full Text] [Related]  

  • 33. Nadolol: a new beta-blocker that may increase patient compliance.
    Gever LN
    Nursing; 1980 Oct; 10(10):57. PubMed ID: 6106172
    [No Abstract]   [Full Text] [Related]  

  • 34. Clinical and hemodynamic effects of celiprolol in essential hypertension.
    Parati G; Ravogli A; Bragato R; Omboni S; Mutti E; Mancia G
    J Cardiovasc Pharmacol; 1989; 14 Suppl 7():S14-21. PubMed ID: 2481785
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nadolol (corgard) in severe and resistant hypertension.
    Nontak MA
    Med J Malaysia; 1981 Sep; 36(3):181-5. PubMed ID: 6120443
    [No Abstract]   [Full Text] [Related]  

  • 36. Renal function in patients with essential hypertension receiving nadolol.
    Waal-Manning HJ; Hobson CH
    Br Med J; 1980 Aug; 281(6237):423-4. PubMed ID: 6107151
    [No Abstract]   [Full Text] [Related]  

  • 37. [The new beta blocker Betapressin. Long-term experience in hypertensive patients in ambulatory care].
    Dameris W
    ZFA (Stuttgart); 1981 Mar; 57(8):628-32. PubMed ID: 6111871
    [No Abstract]   [Full Text] [Related]  

  • 38. Bucindolol in essential hypertension.
    Reid JL; Curzio J; Vincent J
    Int J Clin Pharmacol Res; 1985; 5(5):293-301. PubMed ID: 2866166
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bevantolol vs propranolol: a double-blind controlled trial in essential hypertension.
    Maclean D
    Angiology; 1988 Jun; 39(6):487-96. PubMed ID: 2897812
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Clinical evaluation of the hypotensive effects of nadolol].
    Hanzlik J; Sodolski W; Stelmasiak T; Wolański I
    Kardiol Pol; 1982; 25(2):101-6. PubMed ID: 6125620
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.